Bavencio 200 mg Infusion 10 ml

Bavencio 200 mg Infusion is an anti-cancer medicine used in the treatment of different types of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. This medicine is used in treating Merkel cell carcinoma as first-line therapy in combination with axitinib in patients with renal cell carcinoma and in patients with advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.

Bavencio 200 mg Infusion contains Avelumab, which functions by binding to PD-L1 specifically and preventing it from interacting with PD-1 proteins, thereby prevents the immune system from fighting cancer cells and enables the immune cells to kill the cancer cells.

Bavencio 200 mg Infusion may cause certain side effects such as diarrhoea, nausea, vomiting, tiredness, itching, rash, headache, fever, shortness of breath, muscle/joint pain, loss of appetite and injection site reactions. Inform your doctor if any of these side effects persist for longer. Bavencio 200 mg Infusion will be administered by an oncologist trained in administering anti-cancer agents. 

Avoid receiving Bavencio 200 mg Infusion and inform your doctor if you are allergic to it or any other components of it. Before taking Bavencio 200 mg Infusion, tell your doctor if you have/had liver or kidney disease, autoimmune disorders such as ulcerative colitis or Crohn's disease, a history of organ transplants, heart problems, lung disease, and breathing difficulty. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy. Avoid breastfeeding while taking Bavencio 200 mg Infusion.

Bavencio 200 mg Infusion is used in the treatment of Merkel cell carcinoma, Renal cell carcinoma and Urothelial carcinoma. The detailed uses of Bavencio 200 mg Infusion are as follows:

• Merkel cell carcinoma:Bavencio 200 mg Infusion is used to treat metastatic Merkel cell carcinoma, a rare and aggressive form of skin cancer, in adults and children aged 12 years and older.
• Urothelial carcinoma: Bavencio 200 mg Infusion is used to treat locally advanced or metastatic urothelial carcinoma (a type of bladder or urinary tract cancer) in adults when the disease has progressed after platinum-based chemotherapy.
• Renal cell carcinoma: Bavencio 200 mg Infusion is used in combination with axitinib to treat advanced renal cell carcinoma (kidney cancer) that cannot be removed surgically or has spread to other parts of the body.

• Follow your doctor's instructions on the dosage and timing of this medication.
• Bavencio 200 mg Infusion will be administered by a doctor or nurse in a healthcare facility.
• Do not self-administer.

Bavencio 200 mg Infusion contains Avelumab, which is used in the treatment of different types of cancers. It works by binding to PD-L1 selectively, blocking its interaction with PD-1, the inhibitory T-cell receptor. T-cell-mediated, adaptive antitumour immune responses are produced when PD-L1 inhibition eliminates the suppression of T-cell activity. It blocks its interaction with PD-1 proteins that stop the immune system from attacking the cancer cells; this allows the immune cells to kill the cancer cells.

To treat your condition effectually, continue receiving Bavencio 200 mg Infusion for the period that your doctor has prescribed. Bavencio 200 mg Infusion may cause severe immune-mediated adverse reactions (IMAR) such as immune-mediated colitis, hepatitis, hepatotoxicity, nephritis, endocrinopathies, pneumonitis, cardiac problems, and dermatologic reactions. It may also cause infusion-related reactions in some patients. Therefore, caution should be exercised if you have/had liver or kidney disease, any history of organ transplant, gastrointestinal disorders, autoimmune disorders such as ulcerative colitis or Crohn’s disease, lung disease, heart problems, and breathing difficulty while receiving Bavencio 200 mg Infusion. This medicine may also cause severe infusion-related reactions. Hence, careful monitoring is recommended and discontinue the treatment if any severe infusion reactions occur. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 12 years of age as the safety and efficacy are not established.